Tesamorelin/Ipamorelin

Origin & Classification

This kit combines Tesamorelin, a 44-amino-acid growth hormone-releasing hormone analog, with Ipamorelin, a pentapeptide ghrelin receptor agonist. Both peptides are synthesized independently via recombinant or solid-phase methods and formulated together for research use. The pairing belongs to the class of multi-peptide kits designed to interrogate endocrine signaling.

Mechanism & Research Context

Tesamorelin stimulates the GHRH receptor, while Ipamorelin activates the growth hormone secretagogue receptor (GHSR). By engaging two distinct receptors, the combination allows researchers to study cooperative control of growth hormone secretion. Investigations focus on the kinetics of growth hormone release, receptor cross-talk, intracellular signaling cascades (cAMP and Ca2+ pathways), and feedback inhibition via somatostatin. Studies also explore downstream impacts on IGF-1 production, metabolic pathways, and gene expression. This dual-peptide approach offers insights into how simultaneous modulation of hypothalamic and pituitary receptors can affect the growth hormone axis without implying therapeutic synergy.

Composition & Quality

The Tesamorelin/Ipamorelin kit provides separate vials of lyophilized peptides, each with purity >95 %, as verified by HPLC and mass spectrometry. Production adheres to GMP-aligned standards, including purification, sterile filtration, and quality control. Certificates of analysis accompany the kit, documenting peptide identity, purity, and recommended storage conditions. Users are instructed to reconstitute each peptide separately in sterile aqueous solutions and handle according to guidelines to maintain stability.

Summary & Unified Disclaimer

This description summarizes the scientific context of the molecule. It is provided for educational and research discussion purposes only. It is not intended to diagnose, treat, cure, or prevent any disease, and no medical or consumption claims are made.